Repligen Corporation

RGEN Healthcare Medical Instruments & Supplies

Repligen Corporation’s revenue for fiscal 2025 (year ended December 2025) was $738.3 million, up 16.4% from fiscal 2024. In the quarter to June 2026, revenue grew 11.9%, EPS fell 65.4%, free cash flow grew 27.1% and total debt rose 3.25%, each against the same quarter a year earlier.

175.20 8.97 −4.87%
Market cap
$11.7B
P/E
234×
Fwd P/E
112×
Dividend yield
—
F-score
6/9
Altman Z
7.49
Beneish M
−2.52
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

0.08% 2.40% 2.51% 1.99%
Piotroski F-Score
6 6 7 7
ROA
0.06% 1.69% 1.78% 1.42%
ROIC
0.03% 1.83% 2.16% 2.18%
Return on Tangible Assets
0.15% 4.12% 4.25% 3.36%
Average Days of Receivables
76.81 78.41 72.47 73.32
Free Cash Flow per Share
1.87 1.63 1.86 1.96
Free Cash Flow
105.23 91.93 104.66 110.35
Capital Expenditures
(25.66) (25.49) (26.05) (24.51)
Other line items
Cash ROIC
3.12% 2.69% 3.05% 3.18%
Accounts Receivable Turnover
5.09 5.04 5.11 4.99
Accounts Payable Turnover
15.13 11.33 11.70 12.40
Inventory Turnover
2.24 2.25 2.17 2.13
Average Days of Payables
27.96 31.12 35.12 33.24
Days of Inventory on Hand
152.32 176.75 181.65 186.65
Tax Rate
(0.63) (0.22) (0.09) (0.20)
Research and Development Expense of Revenue
7.34% 7.34% 7.40% 7.26%
Selling, General and Administrative Expense of Revenue
38.95% 39.35% 38.82% 38.47%
Share Based Compensation of Revenue
4.38% 4.42% 4.41% 4.24%
Interest Coverage
0.04 2.56 2.95 2.92
Operating CF/Net income
75.31 2.40 2.54 3.25
Depreciation/Fixed assets
0.49 0.51 0.56 0.58
Capex/Depreciation
(0.27) (0.27) (0.27) (0.25)
Revenue per Share
12.58 13.13 13.55 13.92
Operating CF per Share
2.33 2.09 2.32 2.39
Capex per Share
(0.46) (0.45) (0.46) (0.43)
Capex to Sales
0.04 0.03 0.03 0.03

Fold the line items

Columns are period end dates